Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Brief summary public domain (ClinicalTrials.gov)

Primary Objectives To assess the efficacy of the combination of gemcitabine, taxotere, and xeloda (GTX) with cisplatin in subjects with metastatic pancreatic cancer based on the progression-free survival (PFS) rate at 6 month. Secondary Objectives * To assess safety and characterize toxicities of the combination of GTX with cisplatin in subjects with metastatic pancreatic cancer. * To estimate disease control rate (DCR), PFS, and overall survival (OS). * To estimate a PFS rate of an expansion cohort testing an alternative schedule. Study Design This study is a single arm phase II study to assess the efficacy of GTX with cisplatin in subjects with metastatic pancreatic cancer. Approximately 38 evaluable subjects will be enrolled, 28 in the initial cohort and 10 in the expansion cohort The study will have a safety run-in phase consisting of 6 subjects. To ensure that the combination is safe, the first six subjects will be treated at DL1 and observed for limiting toxicity for the first 2 cycles before continuation with further accrual. After the safety run-in, the study will be continuously monitored for adverse events. The primary endpoint will be the PFS rate at 6 month, which is defined as the proportion of subjects alive, free of disease progression at 6 months. The treatment regimen would be considered of insufficient activity for further study in this population if PFS rate at 6 months is 50% or less, and the minimum required level of efficacy that would warrant further study with the proposed regimen is a 75% PFS rate at 6 months. The study design includes interim monitoring for futility using a predictive probability approach. We will stop the study early if given the information at the interim analysis, it is unlikely that the PFS rate at 6 months will be greater than 50% if the study continues to the end.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months [6 months]. Number, percentage of participants (95% Confidence Interval). Primary Cohort (21 Day Cycle) (n=28): 78.6 (59 to 92); Expansion Cohort (28 Day Cycle) (n=10): 30 (7 to 65).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity [Up to 23 months]. Count Of Participants, Participants. Primary Cohort (21 Day Cycle) (n=29): 26; Expansion Cohort (28 Day Cycle) (n=10): 5.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Disease Control Rate (DCR) [Up to 22 months]. Number, Percentage of Participants (95% Confidence Interval). Primary Cohort (21 Day Cycle) (n=28): 89 (72 to 98).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression-free Survival (PFS) [Up to 21 months]. Median, Months (95% Confidence Interval). Primary Cohort (21 Day Cycle) (n=28): 8.4 (6.58 to 13.72); Expansion Cohort (28 Day Cycle) (n=10): 4.1 (3.74 to NA) [NA means that the upper bound confidence interval was not reached because the sample size was too small to estimate upper limit.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [Up to 28 months]. Median, Months (95% Confidence Interval). Primary Cohort (21 Day Cycle) (n=28): 13.42 (10.48 to 20.13).